Latest news with #ChristianAngermayer
Yahoo
01-07-2025
- Business
- Yahoo
Atai and Beckley, set to merge, reveal study success for psychedelic drug
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Atai Life Sciences and Beckley Psytech are making plans to push the psychedelic drug mebufotenin into Phase 3 testing after it safely and significantly reduced symptoms of treatment-resistant depression in a Phase 2b study. Shares of Atai jumped 20% after the companies' announcement Tuesday. Atai also announced a $50 million private placement in a financing round led by Ferring Ventures and Apeiron Investment, the family office of Atai founder and Chairman Christian Angermayer. With the successful study in hand and a new infusion of cash, the companies are proceeding with plans to merge in the second half of this year. The combination, announced in June, was contingent on positive results from the Phase 2b trial. Atai had previously scooped up a 36% stake in privately held Beckley in 2024. Atai and Beckley are looking to benefit from a new openness to psychedelic drugs for the treatment of mental health conditions. Both Health and Human Services Secretary Robert F. Kennedy Jr. and Food and Drug Administration Commissioner Martin Makary have touted the potential benefits of the medicines for patients, while Johnson & Johnson's Spravato, a derivative of ketamine, has generated blockbuster sales. Investors so far have shown a willingness to support the research but are looking for strong results. Compass Pathways recently failed to meet that mark with a medicine that succeeded in a Phase 3 trial but nevertheless disappointed shareholders by only reducing scores on a scale used to gauge depressive symptoms by a mean difference of 3.6 points compared with placebo. Beckley's mebufotenin showed a difference of 5.3 points and 6.3 points for the two therapeutic doses it tested as compared with a low-dose group used as a control when measured at Day 29 after treatment. Wall Street was looking for a difference of at least 5 points, Jefferies analyst Andrew Tsai wrote in a note to clients. Like Spravato, mebufotenin is administered through the nose. Atai and Beckley said participants in its study generally were able to leave the clinic within 90 minutes, which would put the drug in the conventional treatment window established by Spravato. The study also found no serious side effects and no evidence of suicidal intent or behavior in patients given mebufotenin. Researchers tested an 8 milligram dose and a 12 milligram dose against an 0.3 milligram control. The larger difference in depression symptom measurement was in the 8 mg dose, though the companies said they consider efficacy equivalent between the 8 mg and 12 mg doses. They plan to advance the 8 mg dose into Phase 3 testing after consulting with regulators. The companies said improvements were seen as early as one day after treatment and generally lasted at least eight weeks. While the results need to be confirmed in a continuing open-label study of a second dose and the eventual Phase 3 trial, the data suggests Atai and Beckley may be able to offer a longer window between treatments, possibly giving their drug an advantage over rivals such as Spravato, Tsai said. Recommended Reading Compass' big psychedelic study doesn't impress investors
Associated Press
01-07-2025
- Business
- Associated Press
atai Life Sciences Announces $50 Million Private Placement Financing
NEW YORK and AMSTERDAM, July 01, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) ('atai'), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced it had entered into subscription agreements relating to the purchase of 18,264,840 ordinary shares of atai with a nominal value of €0.10 per share ('Common Shares') and pre-funded warrant to purchase 4,566,210 Common Shares (the 'Pre-Funded Warrant'). The financing is expected to result in gross proceeds of approximately $50 million, before deducting placement agents' fees and other expenses. The net proceeds from the financing are expected to be used by atai for general corporate purposes, including for working capital and to advance the clinical development of the Company's product candidates and programs. The private placement is subject to certain closing conditions, including the expiration of the waiting period pursuant to the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the 'HSR Act') related to the filing expected to be made by Christian Angermayer in connection with Apeiron's investment in this financing. The financing is expected to close in the third quarter of 2025. The financing was co-led by Ferring Ventures S.A. and Apeiron Investment Group, the family office of atai Founder and Chairman Christian Angermayer, with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1. Mr. Angermayer commented: 'With this financing, atai is well-positioned to accelerate its efforts and achieve its goal of delivering new therapeutic options for individuals facing serious mental health challenges. We are confident that these trial results will support a robust discussion with the FDA and allow us have a clear Phase 3 plan early in 2026. I am especially grateful for the repeated support of Ferring Ventures. Their deep understanding of commercialization, market dynamics, and how to build and run effective sales teams is invaluable for atai as it prepares to transform from a clinical-stage biotech into a fully integrated commercial company over time'. Jean-Frederic Paulsen, Chairman, Ferring Ventures S.A., added : 'Psychedelics have demonstrated remarkable potential as a transformative class of treatments for a range of mental health conditions. atai has consistently led innovation and progress in this space, and I am pleased to expand our investment to support atai in pioneering the next generation of mental health treatments.' TD Cowen, Leerink Partners, Guggenheim Securities and Berenberg are acting as joint-lead placement agents for the private placement. The securities being issued and sold in the private placement have not been registered under the Securities Act of 1933, as amended (the 'Securities Act'), or any state's securities laws, and will be issued and sold in a private placement in reliance on Section 4(a)(2) of the Securities Act. The securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. atai granted registration rights to the purchasers in the private placement, and has agreed to file a registration statement with the Securities and Exchange Commission (the 'SEC') registering the resale of the common shares issued in the private placement and the Common Shares issuable upon exercise of the Pre-Funded Warrants issued in the private placement. The offer and sale of the Common Shares underlying the Pre-Funded Warrant have not been registered under the Securities Act. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About atai Life Sciences atai is a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes. atai's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder, which are in Phase 2 clinical development. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD. These programs aim to address the complex nature of mental health providing commercially scalable interventional psychiatry therapies that can integrate seamlessly into healthcare systems. Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'). The words 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'anticipate,' 'initiate,' 'could,' 'would,' 'project,' 'plan,' 'potentially,' 'preliminary,' 'likely,' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things, expectations regarding the closing of the private placement financing including satisfaction and timing of closing conditions, including the closing conditions relating to the HSR Act filing, and expectations regarding the use of proceeds from the proposed financing. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including important factors described in the section titled 'Risk Factors' in our most recent Annual Report on Form 10-K filed with the SEC, as such factors may be updated from time to time in atai's other filings with the SEC. atai disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law. Contact Information Investor Contact: [email protected] atai Media Contact: [email protected]
The Star
14-06-2025
- Sport
- The Star
The founders breaking all barriers, and rules
THE founders of The Enhanced Games, Dr Aron D'Souza and Christian Angermayer, have a vision that goes beyond sport. For them, it's about stretching human achievement to the greatest heights, with whatever means available. In fact, they are encouraging participants of the Games to take performance-enhancement drugs.
Cision Canada
30-05-2025
- Business
- Cision Canada
Super Copper Closes Non-Brokered Private Placement with Apeiron Investment Group
VANCOUVER, BC, May 30, 2025 /CNW/ - SUPER COPPER CORP. (CSE: CUPR) (OTCQB: CUPPF) (FSE: N60) (" Super Copper" or the "Company") is pleased to announce that it has closed its previously announced non-brokered private placement of units (the " Units"), raising gross proceeds of $1,000,000 (the "Offering"). Under the Offering, the Company issued 4,000,000 Units at a price of $0.25 per Unit to Apeiron Investment Group Limited (" Apeiron"), a leading global investment firm founded by entrepreneur and investor Christian Angermayer. Each Unit is comprised of one common share and one common share purchase warrant (a " Warrant"). Each Warrant entitles the holder to acquire an additional common share at a price of $0.30 per common share until May 29, 2028. In exchange for Apeiron providing advisory services to the Company, the Company agreed to grant Apeiron an aggregate of 4,000,000 restricted share units (" RSUs") under its equity incentive plan (the " Plan"), of which 3,000,000 RSUs were granted on closing of the Offering and 1,000,000 RSUs will be granted as soon as permitted under the terms of the Plan. To facilitate the granting of the RSUs, an aggregate of 1,200,000 outstanding options were cancelled. Following closing of the Offering and grant of the RSUs, Apeiron holds approximately 10.99% of the issued and outstanding common shares of the Company on an undiluted basis. The Warrants and the RSUs are subject to a restriction on exercise or conversion that prohibits Apeiron from exercising the Warrants or converting the RSUs if the number of common shares to be issued pursuant to such exercise or conversion would exceed, when aggregated with all other common shares of the Company owned by Apeiron, 19.9% of all of the common shares issued and outstanding at such time, unless the Company has obtained shareholder approval for the creation of a new 'control person', in accordance with the policies of the Canadian Securities Exchange. In addition if any of the RSUs have not been settled by the date that is three years following the date of grant, and the Company has not obtained shareholder approval for the creation of Aperion as a new "control person" and if settlement of the RSUs in common shares would violate the foregoing restriction, then the Company has agreed to settle such RSUs by paying Apeiron cash equal to the fair market value of the common shares underlying such RSUs. In connection with the Offering, the Company's CEO, Zachary Dolesky and all other directors of the Company entered into voluntary lock-up agreements covering an aggregate of 5,817,360 common shares. Mr. Dolesky has agreed to lock up 5,317,360 common shares for so long as Apeiron maintains a minimum ownership stake of 10.0% in the Company (on a partially diluted basis). Additionally, subject to Apeiron maintaining a minimum ownership stake of 10.0% in the Company (on a partially diluted basis), the other directors of the Company have agreed to lock up an additional 500,000 common shares for a term of 18 months. Concurrently with the closing of the Offering, Apeiron and the Company entered into an investor rights agreement, that provides, among other things, Apeiron with certain rights in the event it maintains a minimum ownership stake of 10.0% in the Company (on a partially diluted basis), including: (i) the right to participate in equity financings; (ii) top-up rights in the event of dilutive issuances; and (iii) the right to nominate one person to the Company's board of directors. The proceeds raised from the Offering are expected to be used to accelerate the advancement of Super Copper's flagship Cordillera Cobre project in Chile and support broader business expansion initiatives, including targeted acquisitions and for general working capital purposes including marketing and investor relations. The securities underlying the Units and RSUs are subject to a four month hold period, expiring on September 30, 2025 in accordance with applicable Canadian securities laws. Early Warning Disclosure Pursuant to the Offering, on May 29, 2025, Apeiron acquired 4,000,000 Units, at a price of $0.25 per Unit, for total consideration of $1,000,000, as well as 3,000,000 RSUs. Prior to the completion of the Offering, Apeiron did not hold any securities of the Company. Following the completion of the Offering, Apeiron holds 4,000,000 common shares, 4,000,000 Warrants, and 3,000,000 RSUs, representing approximately 10.99% of the Company's issued and outstanding common shares, on an undiluted basis, or approximately 25.35% of the Company's issued and outstanding common shares, on a partially diluted basis, subject, however, to Apeiron being precluded from exercising Warrants or converting RSUs that would result in Apeiron holding more than 19.9% of the then issued and outstanding common shares of the Company, without the Company first obtaining shareholder approval for the creation of a new 'control person', in accordance with the policies of the Canadian Securities Exchange. Apeiron acquired the securities of the Company for investment purposes. Apeiron may, depending on market and other conditions, increase or decrease its ownership of the Company's securities, whether in the open market, by privately negotiated agreements or otherwise, subject to a number of factors, including general market conditions and other available investment and business opportunities. The disclosure respecting Apeiron's shareholdings contained in this press release is made pursuant to Multilateral Instrument 62-104 Take-Over Bids and Issuer Bids and a report respecting the above acquisition will be filed with the applicable securities commissions using the System of Electronic Document Analysis and Retrieval (SEDAR+) website at Apeiron's registered office is located at 66 & 67, Beatrice, Amery Street, Sliema SLM1707, Malta. About Apeiron Investment Group Apeiron Investment Group is a discretionary investment firm founded and owned by serial entrepreneur Christian Angermayer. At its core, Apeiron is driven by a bold optimism for a future where technology empowers people to live longer, healthier, and more fulfilling lives. Apeiron prides itself on being a hands-on, reliable and long-term partner – committed to supporting founders and emerging asset managers in pushing the boundaries of imagination and shaping the future we aspire to live in. With teams across New York, London, Berlin, Abu Dhabi, and Malta, Apeiron applies a global multi-strategy investment approach, with a primary focus on the US. Apeiron's efforts span direct investments in innovative companies, as well as anchor LP investments combined with minority GP stakes in emerging asset managers. Asset managers Apeiron has stakes in currently manage approximately $5 billion in external capital. Through its proprietary balance sheet, Apeiron's direct investment approach encompasses the entire company lifecycle—from incubating and accelerating breakthrough ideas to scaling growth-stage businesses as well as making impactful investments in listed companies. About Super Copper Corp. Super Copper is a mining exploration company focused on the acquisition, exploration and development of copper and precious metal projects. It is currently developing its joint venture in a prospective Chilean copper property located within the copper-rich Venado Formation in the province of Atacama, Northern Chile, a region with world-class infrastructure and the presence of global majors. | The Canadian Securities Exchange has not reviewed this press release and does not accept responsibility for the adequacy or accuracy of this news release. This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the Company's securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The Company's securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the " 1933 Act") or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available. Forward-Looking Statements This press release contains forward-looking statements regarding future events and the future performance of Super Copper Corp. Forward-looking statements include, but are not limited to: the use of proceeds from the Offering; the grant of 1,000,000 RSUs to Apeiron and the terms thereof;; and Apeiron exercising any of its investor rights under the investor rights agreement with the Company. Forward-looking statements reflect management's beliefs, expectations, and estimates as of the date of this news release. These statements are subject to various risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including, but not limited to: exploration results not meeting expectations; geological interpretations proving incorrect; difficulties in obtaining permits or financing for further exploration; changes in commodity prices and market conditions; and general economic and regulatory factors affecting the mining industry. The words "anticipate," "believe," "expect," "intend," "estimate," "plan," "may," "will," "should," "potential," and similar expressions are intended to identify forward-looking statements. Although Super Copper believes that the expectations and assumptions reflected in these statements are reasonable, no assurance can be given that actual results will be consistent with these forward-looking statements. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Investors should carefully review the risks and uncertainties described in the Company's public filings before making investment decisions.
Yahoo
30-05-2025
- Business
- Yahoo
Super Copper Closes Non-Brokered Private Placement with Apeiron Investment Group
/THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ VANCOUVER, BC, May 30, 2025 /CNW/ - SUPER COPPER CORP. (CSE: CUPR) (OTCQB: CUPPF) (FSE: N60) ("Super Copper" or the "Company") is pleased to announce that it has closed its previously announced non-brokered private placement of units (the "Units"), raising gross proceeds of $1,000,000 (the "Offering"). Under the Offering, the Company issued 4,000,000 Units at a price of $0.25 per Unit to Apeiron Investment Group Limited ("Apeiron"), a leading global investment firm founded by entrepreneur and investor Christian Angermayer. Each Unit is comprised of one common share and one common share purchase warrant (a "Warrant"). Each Warrant entitles the holder to acquire an additional common share at a price of $0.30 per common share until May 29, 2028. In exchange for Apeiron providing advisory services to the Company, the Company agreed to grant Apeiron an aggregate of 4,000,000 restricted share units ("RSUs") under its equity incentive plan (the "Plan"), of which 3,000,000 RSUs were granted on closing of the Offering and 1,000,000 RSUs will be granted as soon as permitted under the terms of the Plan. To facilitate the granting of the RSUs, an aggregate of 1,200,000 outstanding options were cancelled. Following closing of the Offering and grant of the RSUs, Apeiron holds approximately 10.99% of the issued and outstanding common shares of the Company on an undiluted basis. The Warrants and the RSUs are subject to a restriction on exercise or conversion that prohibits Apeiron from exercising the Warrants or converting the RSUs if the number of common shares to be issued pursuant to such exercise or conversion would exceed, when aggregated with all other common shares of the Company owned by Apeiron, 19.9% of all of the common shares issued and outstanding at such time, unless the Company has obtained shareholder approval for the creation of a new 'control person', in accordance with the policies of the Canadian Securities Exchange. In addition if any of the RSUs have not been settled by the date that is three years following the date of grant, and the Company has not obtained shareholder approval for the creation of Aperion as a new "control person" and if settlement of the RSUs in common shares would violate the foregoing restriction, then the Company has agreed to settle such RSUs by paying Apeiron cash equal to the fair market value of the common shares underlying such RSUs. In connection with the Offering, the Company's CEO, Zachary Dolesky and all other directors of the Company entered into voluntary lock-up agreements covering an aggregate of 5,817,360 common shares. Mr. Dolesky has agreed to lock up 5,317,360 common shares for so long as Apeiron maintains a minimum ownership stake of 10.0% in the Company (on a partially diluted basis). Additionally, subject to Apeiron maintaining a minimum ownership stake of 10.0% in the Company (on a partially diluted basis), the other directors of the Company have agreed to lock up an additional 500,000 common shares for a term of 18 months. Concurrently with the closing of the Offering, Apeiron and the Company entered into an investor rights agreement, that provides, among other things, Apeiron with certain rights in the event it maintains a minimum ownership stake of 10.0% in the Company (on a partially diluted basis), including: (i) the right to participate in equity financings; (ii) top-up rights in the event of dilutive issuances; and (iii) the right to nominate one person to the Company's board of directors. The proceeds raised from the Offering are expected to be used to accelerate the advancement of Super Copper's flagship Cordillera Cobre project in Chile and support broader business expansion initiatives, including targeted acquisitions and for general working capital purposes including marketing and investor relations. The securities underlying the Units and RSUs are subject to a four month hold period, expiring on September 30, 2025 in accordance with applicable Canadian securities laws. Early Warning Disclosure Pursuant to the Offering, on May 29, 2025, Apeiron acquired 4,000,000 Units, at a price of $0.25 per Unit, for total consideration of $1,000,000, as well as 3,000,000 RSUs. Prior to the completion of the Offering, Apeiron did not hold any securities of the Company. Following the completion of the Offering, Apeiron holds 4,000,000 common shares, 4,000,000 Warrants, and 3,000,000 RSUs, representing approximately 10.99% of the Company's issued and outstanding common shares, on an undiluted basis, or approximately 25.35% of the Company's issued and outstanding common shares, on a partially diluted basis, subject, however, to Apeiron being precluded from exercising Warrants or converting RSUs that would result in Apeiron holding more than 19.9% of the then issued and outstanding common shares of the Company, without the Company first obtaining shareholder approval for the creation of a new 'control person', in accordance with the policies of the Canadian Securities Exchange. Apeiron acquired the securities of the Company for investment purposes. Apeiron may, depending on market and other conditions, increase or decrease its ownership of the Company's securities, whether in the open market, by privately negotiated agreements or otherwise, subject to a number of factors, including general market conditions and other available investment and business opportunities. The disclosure respecting Apeiron's shareholdings contained in this press release is made pursuant to Multilateral Instrument 62-104 Take-Over Bids and Issuer Bids and a report respecting the above acquisition will be filed with the applicable securities commissions using the System of Electronic Document Analysis and Retrieval (SEDAR+) website at Apeiron's registered office is located at 66 & 67, Beatrice, Amery Street, Sliema SLM1707, Malta. About Apeiron Investment Group Apeiron Investment Group is a discretionary investment firm founded and owned by serial entrepreneur Christian Angermayer. At its core, Apeiron is driven by a bold optimism for a future where technology empowers people to live longer, healthier, and more fulfilling lives. Apeiron prides itself on being a hands-on, reliable and long-term partner – committed to supporting founders and emerging asset managers in pushing the boundaries of imagination and shaping the future we aspire to live in. With teams across New York, London, Berlin, Abu Dhabi, and Malta, Apeiron applies a global multi-strategy investment approach, with a primary focus on the US. Apeiron's efforts span direct investments in innovative companies, as well as anchor LP investments combined with minority GP stakes in emerging asset managers. Asset managers Apeiron has stakes in currently manage approximately $5 billion in external capital. Through its proprietary balance sheet, Apeiron's direct investment approach encompasses the entire company lifecycle—from incubating and accelerating breakthrough ideas to scaling growth-stage businesses as well as making impactful investments in listed companies. About Super Copper Corp. Super Copper is a mining exploration company focused on the acquisition, exploration and development of copper and precious metal projects. It is currently developing its joint venture in a prospective Chilean copper property located within the copper-rich Venado Formation in the province of Atacama, Northern Chile, a region with world-class infrastructure and the presence of global majors. | The Canadian Securities Exchange has not reviewed this press release and does not accept responsibility for the adequacy or accuracy of this news release. This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the Company's securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The Company's securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act") or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available. Forward-Looking Statements This press release contains forward-looking statements regarding future events and the future performance of Super Copper Corp. Forward-looking statements include, but are not limited to: the use of proceeds from the Offering; the grant of 1,000,000 RSUs to Apeiron and the terms thereof;; and Apeiron exercising any of its investor rights under the investor rights agreement with the Company. Forward-looking statements reflect management's beliefs, expectations, and estimates as of the date of this news release. These statements are subject to various risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including, but not limited to: exploration results not meeting expectations; geological interpretations proving incorrect; difficulties in obtaining permits or financing for further exploration; changes in commodity prices and market conditions; and general economic and regulatory factors affecting the mining industry. The words "anticipate," "believe," "expect," "intend," "estimate," "plan," "may," "will," "should," "potential," and similar expressions are intended to identify forward-looking statements. Although Super Copper believes that the expectations and assumptions reflected in these statements are reasonable, no assurance can be given that actual results will be consistent with these forward-looking statements. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Investors should carefully review the risks and uncertainties described in the Company's public filings before making investment decisions. SOURCE Super Copper Corp. View original content to download multimedia: Sign in to access your portfolio
